Molecular imaging of biomarkers in breast cancer

Abstract

Breast cancer therapy is one of the biggest successes, ultimately defined by clinical endpoints such as survival. It is very precious to have biomarkers that can forecast the most efficacious therapies or measure response to therapy early in treatment. Molecular imaging has a promising role in complementing and overcoming some of the limitations of traditional biomarkers by providing the ability to perform non-invasive, repeatable whole-body assessments. The potential advantages of imaging biomarkers are apparent, and initial clinical studies have been promising, but proof of clinical utility still requires prospective multi-center clinical trials.